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BACKGROUND: The aim of this study was to determine the activity of anthracycline rechallenge using pegylated liposomal doxorubicin
(PLD) in patients with metastatic breast cancer (MBC) previously treated with conventional anthracyclines.
METHODS: Pooled individual data from four prospective trials were used, and the primary end point of the pooled analysis was clinical
benefit rate (CBR). The studies comprised 935 patients, of whom 274 had received PLD in the metastatic setting after prior exposure
to conventional anthracyclines (rechallenge population).
RESULTS: The majority of patients were heavily pretreated. Previous anthracycline therapy was administered in the adjuvant (14%) or
metastatic setting (46%), or both (40%). The overall CBR from rechallenge with PLD was 37.2% (95% CI, 32.4–42.0). In univariate
analyses, the CBR was significantly higher in patients with less exposure to prior chemotherapy, in taxane-naive patients, and in
patients with a favourable Eastern Cooperative Group performance status of 0 vs 1 vs 2 (53.3 vs 35.5 vs 18.2%; Po0.001). In
multivariate analyses, performance status proved to be the only independent predictor of the CBR achieved with PLD rechallenge
(P¼0.038). There was no statistically significant difference in CBR regarding the setting, cumulative dose of and/or resistance to prior
anthracyclines, or time since prior anthracycline administration.
CONCLUSION: Anthracycline rechallenge using PLD is effective in patients with MBC who have a favourable performance status,
regardless of setting, resistance, cumulative dose or time since prior conventional anthracycline therapy.
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In Europe and the United States, breast cancer remains the number
one diagnosed cancer in women (incidence rate approximately
28%); and in Europe, it is the leading cause of death from cancer in
women (Ferlay et al, 2007; Jemal et al, 2009). Though the majority
of women with early-stage disease receive adjuvant systemic
treatment to prevent disease recurrence, approximately 30–70% of
patients develop metastatic breast cancer (MBC) (Early Breast
Cancer Trialists’ Group, 2005; Cardoso et al, 2009). MBC patients
represent a very heterogeneous population, and the number of
available therapies for MBC is rapidly growing. Anthracyclines and
taxanes remain the most active cytotoxic agents in the treatment of
this disease, and as such, have been widely integrated into adjuvant
regimens for early-stage breast cancer (Early Breast Cancer
Trialists’ Group, 2005; Beslija et al, 2009; Cardoso and Castiglione,
2009; Cardoso et al, 2009).
Clinicians still face a significant challenge in the choice of
treatment for patients with MBC who have failed one or more
chemotherapy regimens. The repeated use of conventional
anthracyclines is still believed to be limited by cumulative cardiac
toxicity (Jones et al, 2006; Ryberg et al, 2008). Doxorubicin
cardiotoxicity is dose dependent. The average incidence of
doxorubicin-related cardiotoxicity is 5.1% in women who have
received cumulative doses of 400mgm
 2 (Von Hoff et al, 1979;
Swain et al, 2003). The incidence of cardiotoxicity exponentially
increases with a cumulative dose of 500mgm
 2. This treatment-
related cardiotoxicity, specifically linked to anthracycline use in
these patients, has remained a challenge for physicians, and thus
research in this area is increasing.
Because the majority of pretreated patients with MBC have been
exposed to anthracyclines, either in the adjuvant or metastatic
settings, there is a need for a cardiac tolerable and effective
approach. Pegylated liposomal anthracycline formulations, such as
pegylated liposomal doxorubicin (PLD, Caelyx; Schering-Plough,
Kenilworth, NJ, USA), represent an attractive option in this setting.
Single-agent PLD has repeatedly demonstrated comparable
efficacy to doxorubicin, with less cumulative cardiac toxicity and
less myelosuppression (Gabizon and Martin, 1997; O’Shaughnessy,
2003; Keller et al, 2004; O’Brien et al, 2004; Theodoulou and Hudis,
2004). Moreover, data suggest efficacy of PLD in the anthracycline
rechallenge setting (Keller et al, 2004; O’Brien et al, 2004; Al-Batran
et al, 2006a,b; Trudeau et al, 2009).
There is no consensus about which parameters should be used
in the decision regarding anthracycline rechallenge. Criteria
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sclinicians need to consider include prior anthracycline treatment,
prior taxane exposure, previous radiation, patient performance
status, cardiac history and cardiac function, age and other
co-variants. Two important factors, time since prior anthracycline
therapy and cumulative dose of anthracycline, have been identified
as predictive factors for the efficacy of anthracycline rechallenge in
some studies; however, they have not been validated (Singal and
Iliskovic, 1998).
Thus, we conducted a pooled analysis on individual patient data
of MBC populations who received single-agent PLD rechallenge
after previous exposure to conventional anthracyclines. The
primary objective was clinical benefit rate (CBR). The secondary
objective was to determine clinical factors that may predict the
efficacy of PLD in anthracycline-pretreated patients with MBC.
MATERIALS AND METHODS
Literature search and identification of studies
The aim of this study was to identify all relevant published
prospective randomised clinical trials evaluating PLD as mono-
therapy in patients with MBC. A literature search was performed
using databases (PubMed, CANCERLIT, the Cochrane Library and
clinicaltrials.gov).
Study selection
Eligible trials were prospective, in which patients received single-
agent PLD for metastatic disease and included at least a subgroup
of patients who had been pretreated with conventional anthracy-
clines. Four trials were identified from these searches for inclusion
(Table 1; Keller et al, 2004; O’Brien et al, 2004; Al-Batran et al,
2006a,b). The databases of these studies were provided by Merck,
formerly Schering Plough Corp. The analysis was performed
with the permission of the ethics committee responsible for our
institution.
Study objectives and data extraction
The primary end point, CBR, was defined as objective response,
which included complete response, partial response or stable
disease lasting longer than 6 months. Rechallenge with PLD was
considered efficacious if the CBR exceeded 30%, whereas below
20% was considered inactive. The rate of 30% was considered
clinically relevant taking into account the heavily pretreated
population. Post hoc calculations provided 98% power to detect a
CBR rate 430% (A’Hern, 2001).
Pre-specified clinical parameters, including baseline Eastern
Cooperative Group (ECOG) performance status, number of
previous chemotherapies, previous taxane, age, setting of prior
anthracycline, cumulative dose of prior anthracycline, anthracy-
cline-free interval and anthracycline resistance were evaluated for
their association with the CBR, response rate (RR), progression-
free survival (PFS) and overall survival (OS). Anthracycline
resistance was defined as having disease progression while on
anthracycline-based therapy for metastatic disease, or within
6 months of receiving adjuvant anthracycline treatment.
Table 1 Trial characteristics
Al-Batran et al (2006a) Al-Batran et al (2006b) Keller et al (2004) O’Brien et al (2004)
Date first patient enroled May 2000 October 2001 June 1997 June 1998
No. of patients
Total/received PLD/received
PLD after prior CAC
79/79/79 46/46/33 301/150/124 509/254/38
Study design Non-randomised phase II Non-randomised phase II Randomised phase III with PLD vs
comparator
a
Randomised phase III with
PLD vs doxorubicin
Study population Women with at least 1 prior
chemotherapy for MBC
Women with at least 1 prior
chemotherapy for MBC
Women with taxane refractory MBC
and p2 prior chemotherapies for
metastatic disease
Women, previously untreated
for metastatic disease
Response assessment scale WHO WHO NK WHO
PLD schedule 50mgm
 2 every 4 weeks 40mgm
 2 every 4 weeks 50mgm
 2 every 4 weeks 50mgm
 2 every 4 weeks
Abbreviations: PLD¼pegylated liposomal doxorubicin; MBC¼metastatic breast cancer; CAC¼conventional anthracycline; WHO World Health Organization; NK¼not
known.
aVinorelbine or mitomycin C plus vinblastine.
Table 2 Distribution of predefined clinical parameters
N (%)
Age
18–65 years 222 (81.0)
465 years 52 (19.0)
ECOG performance status
0 75 (27.4)
1 154 (56.2)
2 44 (16.0)
Unknown 1 (0.4)
No. of prior therapies
a
1 18 (6.6)
2 62 (22.6)
42 194 (70.8)
Previous taxane
Yes 198 (72.3)
No 66 (24.1)
Unknown 10 (3.6)
Anthracycline-free interval
0–12 months 96 (35.1)
412 months 150 (54.7)
Unknown 28 (10.2)
Setting of prior anthracycline exposure
Adjuvant only 38 (13.9)
Metastatic only 126 (46.0)
Both 110 (40.1)
Cumulative dose of prior anthracycline
o180mgm
 2 79 (28.8)
180–250mgm
 2 73 (26.7)
4250mgm
 2 88 (32.1)
Unknown 34 (12.4)
Anthracycline resistance
Yes 118 (43.1)
No 138 (50.4)
Unknown 18 (6.5)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aIncluding chemo-
therapy and hormonal therapy in the adjuvant and metastatic setting.
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Heterogeneity between studies was tested using the log-rank
test for PFS and OS and the Fisher’s exact test for CBR, RR and
baseline parameters. The same statistical tests and models were
applied to assess the univariate relationship between predefined
variables and the primary and secondary end points. Furthermore,
Cox proportional hazard models and logistic regression
models were used for the multivariate analysis. In a secondary
analysis, the univariate results were adjusted for baseline
performance status, prior taxane therapy and number of previous
chemotherapy regimens (these factors were found to be hetero-
geneous among the populations). Time-to-event curves was
calculated by the Kaplan–Meier method. All P-values were two
sided, with P-values o0.05 considered to indicate statistical
significance.
RESULTS
Characteristics of the patients
Of the 935 patients included in this analysis, 274 (29.3%) received
PLD and had at least one prior conventional anthracycline therapy.
The distribution of the predefined clinical parameters in the
pooled population is shown in Table 2. The median age of the
patients was 56 years (range, 29–87 years). Patients had a median
of 3.5 prior treatment lines (range, 1–9), and 93.4% had at least
two previous therapies (including chemotherapy and hormonal
therapy). Prior anthracycline therapy was mostly administered in
the metastatic setting, with prior anthracycline being adjuvant
(14%), metastatic (46%) or in both settings (40%). Patients
received a median of three cycles of PLD (range, 1–18), with a
median dose of 83.8mg per cycle and a mean cumulative dose of
Table 3 Clinical benefit rate
Overall Al-Batran et al (2006a) Al-Batran et al (2006b) Keller et al (2004) O’Brien et al (2004)
No. of patients 274 79 33 124 38
CBR, n (%) 102 (37.2) 30 (38.0) 8 (24.2) 37 (29.8) 27 (71.1)
95% CI 32.4–42.0 29.0–47.0 12.0–36.5 23.1–36.6 59.0–83.2
No CB, n (%) 170 (62) 49 (62) 25 (75.8) 85 (68.5) 11 (28.9)
NE, n (%) 2 (0.7) — — 2 (1.6) —
Abbreviations: CBR¼clinical benefit rate; CB¼clinical benefit; NE¼not evaluable for clinical benefit.
Table 4 Univariate analysis of outcomes according to clinical parameters
Variable
CBR,
n (%)
a P-value
RR,
n (%)
a P-value
Median PFS
(months) P-value
Median OS
(months) P-value
Age
18–65 years 83/220 (37.7) 26/172 (15.1) 3.2 10.7
465 years 19/52 (36.5) 1 8/38 (21.1) 0.638 2.8 0.439 11.9 0.632
ECOG performance status
0 40/75 (53.3) 17/59 (28.8) 4.1 15.5
1 54/152 (35.5) 14/122 (11.5) 3.4 11.4
2 8/44 (18.2) o0.001 3/28 (10.7) 0.001 1.7 o0.001 4.1 0.001
No. previous chemotherapies
b
1 10/18 (55.6) 4/16 (25.0) 4.55 18.3
2 15/61 (24.6) 8/55 (14.5) 2.9 9.3
42 77/193 (39.9) 0.024 22/139 (15.8) 0.415 3.1 0.405 10.9 0.041
Previous taxane
Yes 59/196 (30.1) 17/146 (11.6) 2.8 9.9
No 35/66 (53.0) 0.001 14/56 (25.0) 0.048 4.3 0.191 14.5 0.023
Setting of prior anthracycline
Adjuvant 13/36 (36.1) 2/30 (6.7) 2.9 8.5
Metastatic 53/126 (42.1) 24/102 (23.5) 3.7 11.9
Both 36/110 (32.7) 0.332 8/78 (10.3) 0.050 2.6 0.949 11.2 0.439
Cumulative dose prior anthracycline
o180mgm
 2 26/77 (33.8) 10/59 (16.9) 2.8 9.3
180–250mgm
 2 27/73 (37.0) 8/55 (14.6) 2.8 11.9
4250mgm
 2 31/88 (35.2) 0.913 8/73 (11.0) 0.697 3.1 0.616 12.3 0.333
Anthracycline-free interval
0–12 months 28/96 (29.2) 9/74 (12.2) 2.6 10.7
412 months 61/150 (40.7) 0.078 20/120 (16.7) 0.429 3.2 0.253 11.9 0.892
Anthracycline resistance
Yes 47/138 (40.5) 18/91 (19.8) 3.3 11.3
No 47/116 (34.1) 0.300 14/104 (13.5) 0.237 3.0 0.604 11.1 0.611
Abbreviations: CBR¼clinical benefit rate; RR¼response rate (partial+complete response); PFS¼progression-free survival time; OS¼overall survival time.
an¼number of
patients who were evaluable for predefined parameter and end point.
bIncluding chemotherapy and hormonal therapy in the adjuvant and metastatic setting.
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between the studies regarding baseline ECOG performance status,
taxane pretreatment and number of prior chemotherapy regimens.
This heterogeneity was found to be attributed to the study by
O’Brien et al (2004), which enrolled patients previously untreated
in the metastatic setting (Table 1).
Overall clinical benefit rate
Clinical benefit rate is shown in Table 3 (O’Brien et al, 2004;
Keller et al, 2004; Al-Batran et al, 2006a,b). The overall CBR was
37.2% (95% CI, 32.4–42.0). The lower boundary of the 95%
confidence interval of the CBR observed was above the pre-defined
30% rate. The logistic regression model showed a higher CBR
in the study by O’Brien (Po0.001) as compared with the study
by Keller. In the pooled population, median PFS and OS were 3
(95% CI, 2.8–3.7 months) and 11.1 months (95% CI, 8.9–13.1
months), respectively.
Outcomes according to clinical parameters: univariate
analyses
Clinical benefit rate, RR, PFS and OS according to clinical
parameters are shown in Table 4. There was no difference in
CBR between patients who were considered anthracycline resistant
and those who were not (40.5 vs 34.1%; P¼0.300). There also was
no difference in CBR between patients who received prior
anthracycline in the adjuvant setting (34.2%), in the metastatic
setting (42.1%), or both settings (32.7%), P¼0.332. There were no
significant differences in CBR between patients who had low,
medium or high cumulative doses of prior anthracycline at
baseline (33.8 vs 37.0 vs 35.2%, respectively; P¼0.913). A trend
towards higher CBR was detected in patients who received
PLD 412 months vs p12 months since the end of their prior
anthracycline therapy (40.7 vs 29.2%; P¼0.078). The adjustment
for ECOG performance status, taxane pretreatment and number of
prior chemotherapies revealed similar results (data not shown).
Among clinical parameters not associated with prior anthra-
cycline therapy, ECOG performance status was the strongest
predictor of clinical benefit; CBR was 53.3, 35.5 and 18.2% in
patients with ECOG performance status of 0, 1 and 2, respectively
(Po0.001). In addition, a statistically significant higher RR, longer
PFS and OS were observed for patients with ECOG performance
status of 0 and 1 vs 2 (Table 4; Figure 1). Significantly higher CBRs
were also observed in taxane-naive patients (53.0%) vs patients
who received a previous taxane (30.1%), P¼0.001, and in patients
who failed only one therapy vs more than one therapy (1 vs 2 vs 3:
55.6 vs 24.6 vs 39.9%, respectively; P¼0.024). Age was not a
predictor of CBR. The univariate results regarding CBR were
adjusted for ECOG performance status, taxane pretreatment and
number of prior chemotherapies using a logistic regression model.
The results were similar to the unadjusted models (data not
shown).
Multivariate analyses
All clinical parameters were included in a logistic regression model
to determine their predictive effect on CBR. ECOG performance
status was a strong predictor of CBR (P¼0.038). The number of
prior chemotherapies was no longer a significant predictor of CBR
(P¼0.192), and taxane pretreatment showed a non-significant
trend (P¼0.072). None of the other clinical parameters was
statistically significant. In a multivariate Cox regression analysis,
ECOG performance status also was a significant predictor of
PFS (P¼0.002) and OS (Po0.001). The number of prior
chemotherapies was a significant predictor of OS (P¼0.041).
DISCUSSION
This pooled analysis on the largest data set of MBC patients who
were pretreated with an anthracycline evaluates the efficacy of
anthracycline rechallenge using PLD. All patients had received
conventional anthracyclines, and 72% had received prior taxane
therapy. The majority were pretreated with more than one line of
chemotherapy for metastatic disease. Therefore, most patients in
this analysis were in an advanced and palliative course of their
disease when they received PLD as an anthracycline rechallenge.
Accordingly, we chose CBR as the primary end point for this
patient population rather than RR or PFS (Ohorodnyk et al, 2009).
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Figure 1 Progression-free and overall survival under pegylated liposomal
doxorubicin therapy in patients previously treated with conventional
anthracyclines Eastern Cooperative Oncology Group performance status.
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or a long-lasting stable disease is documented. This reflects a direct
and real effect of the rechallenge. Overall survival was not selected
as the primary objective because it is influenced by other
parameters such as further therapies and prognostic factors (Saad
et al, 2010). The primary assumption of this study, that CBR
430%, was met in this analysis, where 37.2% of patients exhibited
a clinical benefit from rechallenge with PLD (95% CI, 32.4–42.0).
In the univariate analysis, patients with less exposure to prior
treatment (i.e., one prior regimen or taxane naive) exhibited a
statistically significantly higher CBR (53–56%) than patients
that had received two or more prior regimens or prior taxane
(25–36%). Moreover, patients with a favourable ECOG perfor-
mance status (0 or 1) exhibited a statistically significantly higher
CBR than patients with impaired ECOG performance status (2)
(36–53 vs 18.2%, respectively).
In the multivariate analysis, ECOG performance status was
determined to be the only independent predictor of the efficacy of
anthracycline rechallenge with PLD. The ECOG performance status
is widely used to quantify the functional status of cancer patients
and is a common and consistent prognostic factor (Yates et al,
1980). However, the ECOG performance status can also predict the
efficacy of a particular treatment, as patients with a better
performance status are more likely to be compliant and maintain
treatment duration and dose intensity (Nash et al, 1980; Sjo ¨stro ¨m
and Blomqvist, 1996; Robain et al, 2000).
In contrast, no statistically significant differences in CBR were
found in this pooled analysis for the following predefined
parameters related to prior anthracycline therapy: (1) treatment
setting for prior anthracycline administration, (2) anthracycline
cumulative dose, (3) resistance to anthracycline and (4) anthracy-
cline-free interval. These results translate into an expected
significant efficacy from PLD rechallenge if the patient has an
ECOG performance status of 0 or 1 (or conversely a poor efficacy if
the patient has an ECOG performance status of 2), regardless of the
number and type of prior therapies as well as prior anthracycline
exposure. Notably, the lack of association between efficacy of
anthracycline rechallenge and the parameters related to prior
anthracycline therapy apply to the threshold definitions used
in our study. It is possible that if alternative thresholds were used
for the definitions of our parameters, then we would have
encountered a different result in this analysis. Overall, the results
of our study support the need to identify molecular-based
predictive factors for anthracycline efficacy (Pritchard et al,
2008; Gianni et al, 2009).
In the recent literature, the rates of clinical benefit achieved with
combination therapies in MBC patients varied between 39 and 80%
in first-line patients, and 34 and 71% in patients previously treated
for metastatic disease (Blum et al, 2006; Moulder et al, 2008; Silva
et al, 2008; Osako et al, 2009; Ciruelos et al, 2010; Tan et al, 2010).
Therefore, given the characteristics of our population and that
single-agent therapy was used, the overall CBR of 37% observed in
our study, is clinically meaningful and supports efficacy of an
anthracycline rechallenge with PLD. This finding is in agreement
with published reports that show activity and support the use of
anthracyclines in anthracycline-pretreated patients (Gennari et al,
2004; Beslija et al, 2009; Katsumata et al, 2009; Krell et al, 2009).
Notably, this analysis was not specifically designed to address the
question of the first-line use of PLD after adjuvant anthracycline-
based therapy. In the first-line setting, higher objective response
and CBRs are observed after anthracycline rechallenge with
PLD-containing combination chemotherapy (Overmoyer et al,
2005; Sparano et al, 2009; Trudeau et al, 2009).
The important question from findings of our pooled analysis is
how these results fit into the evolving individualised field of
chemotherapy for women with MBC. The ever-growing options for
treatment coupled with biologically tailored research pose a
challenge for clinicians. As a result, oncologists are increasingly
shifting towards a more individualised treatment strategy based on
factors such as patient and tumour characteristics, patient input
and prior therapies. Our study justifies considering anthracycline
rechallenge with PLD as one option for patients with MBC, who
failed conventional anthracyclines or more agents in the adjuvant,
metastatic or both settings, if the performance status of the
patients is still favourable (i.e., ECOG performance status 0 or 1).
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